Literature DB >> 31832976

Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope technology.

Ahmed Musa Hago Bakheet1, Chang Zhao1, Jian-Ning Chen1, Jing-Yue Zhang1, Jun-Ting Huang1, Yu Du1, Li-Ping Gong1, Yuan-Hua Bi1, Chun-Kui Shao2.   

Abstract

BACKGROUND: The diagnostic and prognostic values of glypican3 (GPC3) and glutamine synthetase (GS) proteins in hepatocellular carcinoma (HCC) have been reported, but their specificity and sensitivity remain low. Here, we applied RNAscope to improve HCC early pathological and differential diagnosis by estimating GPC3 and GS mRNAs.
METHODS: We performed RNAscope and immunohistochemistry (IHC) to detect GPC3 and GS biomarkers on the tissue sections of 194 cases, including high- and low-grade liver dysplastic nodules; highly, moderately, and poorly differentiated HCCs; intrahepatic cholangiocarcinomas (ICCs); metastatic HCC; and carcinomas from other organs.
RESULTS: The results showed that all the cases that were negative for GPC3 by RNAscope were also negative for this protein by IHC. The use of RNAscope assay improved the GPC3 and GS specificity and sensitivity by 20-30%. Hence, HCC shows early recognition and upgrades the metastatic HCC differentiation by 23% compared with IHC (p = 0.0001, 0.0064). Meanwhile, all liver cirrhosis, cholangiocytes and non-HCC samples were negative for GPC3 and GS except lymphocytes in lymphomas, and 2 (8.3%) out of the 24 ICC samples but not in the cancer cells.
CONCLUSION: RNAscope for GPC3 and GS panel was highly specific and sensitive for the pathological identification of dysplastic nodules, early stages of HCCs, and would differentiate them from HCCs and metastatic tumors compared with IHC.

Entities:  

Keywords:  Early diagnosis; Liver cancer; Pathological biomarker; RNAscope

Year:  2019        PMID: 31832976     DOI: 10.1007/s12072-019-10006-z

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  6 in total

1.  Abnormal expression of HNRNPA3 in multistep hepatocarcinogenesis.

Authors:  Xinlu Ren; Yi Dong; Miao Duan; Hui Zhang; Peng Gao
Journal:  Oncol Lett       Date:  2020-11-17       Impact factor: 2.967

2.  ER-positive endocervical adenocarcinoma mimicking endometrioid adenocarcinoma in morphology and immunohistochemical profile: A case report of application of HPV RNAscope detection.

Authors:  Ruichao Chen; Ping Qin; Qiuping Luo; Wen Yang; Xuexian Tan; Tonghui Cai; Qingping Jiang; Hui Chen
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

3.  Co-expression of SOX2 and HR-HPV RISH predicts poor prognosis in small cell neuroendocrine carcinoma of the uterine cervix.

Authors:  Shi-Wen Zhang; Rong-Zhen Luo; Xiao-Ying Sun; Xia Yang; Hai-Xia Yang; Si-Ping Xiong; Li-Li Liu
Journal:  BMC Cancer       Date:  2021-03-31       Impact factor: 4.430

4.  Comparison of RNAscope and immunohistochemistry for evaluation of the UPK2 status in urothelial carcinoma tissues.

Authors:  Jiangli Lu; Ming Zhao; Chenyan Wu; Chengbiao Chu; Chris Zhiyi Zhang; Yun Cao
Journal:  Diagn Pathol       Date:  2022-01-14       Impact factor: 2.644

5.  A robust experimental and computational analysis framework at multiple resolutions, modalities and coverages.

Authors:  M Tran; S Yoon; M Teoh; S Andersen; P Y Lam; B W Purdue; A Raghubar; S J Hanson; K Devitt; K Jones; S Walters; J Monkman; A Kulasinghe; Z K Tuong; H P Soyer; I H Frazer; Q Nguyen
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

6.  Evaluation of the Suitability of RNAscope as a Technique to Measure Gene Expression in Clinical Diagnostics: A Systematic Review.

Authors:  Sameeha Atout; Shaymaa Shurrab; Carolyn Loveridge
Journal:  Mol Diagn Ther       Date:  2021-12-26       Impact factor: 4.074

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.